EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11319-11332

  Lu, Juan ^a   Zhao, Fei Peng ^a   Peng, Zengliu ^a   Zhang, Meng Wen ^a   Lin, Shao Xiong ^a,b   Liang, Bi Jun ^a   Zhang, Bao ^a   Liu, Xiong ^a   Wang, Lu ^a   Li, Gang ^a   Tian, Wen Dong ^a   Peng, Ying ^c   He, Ming Liang ^d   Li, Xiang Ping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiogenesis; Endothelin 1; EZH2; miR 1; Nasopharyngeal carcinoma

Indexed keywords

ENDOTHELIN 1; MICRORNA 1; TRANSCRIPTION FACTOR EZH2; 3' UNTRANSLATED REGION; ANGIOGENESIS INHIBITOR; EZH2 PROTEIN, HUMAN; MICRORNA; MIRN1 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER STAGING; CAPILLARY DENSITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHICK EMBRYO; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; NASOPHARYNX TUMOR; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANGIOGENESIS INHIBITORS; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; ENDOTHELIN-1; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYCOMB REPRESSIVE COMPLEX 2; TRANSFECTION;

EID: 84917704471     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2435     Document Type: Article

References (47)

1. Wei WI and Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365(9476):2041-2054.
2. Weis SM and Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11):1359-1370.
3. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R and Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol. 2000; 157(5):1703-1711.
4. Bagnato A and Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab. 2003; 14(1):44-50.
5. Rosano L, Spinella F and Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013; 13(9):637-651.
6. Sparmann A and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-856.
7. Sauvageau M and Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7(3):299-313.
8. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A and Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012; 31(3-4):753-761.
9. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011; 71(1):225-233.
10. Yu L, Lu J, Zhang B, Liu X, Wang L, Li SY, Peng XH, Xu X, Tian WD and Li XP. miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett. 2013; 5(4):1223-1228.
11. Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012; 31(5):583-594.
12. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3(6):401-410.
13. Zhai H, Song B, Xu X, Zhu W and Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013; 32(12):1570-1579.
14. Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang Y, Lehrmann E, Becker KG, Shaknovich R, Liu Z and Gartenhaus RB. Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet. 2014; 10(1):e1004105.
15. Leng R, Zha L and Tang L. MiR-718 represses VEGF and inhibits ovarian cancer cell progression. FEBS Lett. 2014; 588(12):2078-2086.
16. Xue M, Yao S, Hu M, Li W, Hao T, Zhou F, Zhu X, Lu H, Qin D, Yan Q, Zhu J, Gao SJ and Lu C. HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway. Nucleic Acids Res. 2014 Aug 7.
17. Ma L, Teruya-Feldstein J and Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-688.
18. Urbich C, Kuehbacher A and Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008; 79(4):581-588.
19. Nohata N, Hanazawa T, Enokida H and Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012; 3(1):9-21.
20. Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, Su X, Peng J, Gao H, Tan Y, Zhao Z, Li Y, Qi Z, Rui Y and Zhang T. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012; 91(11-12):440-447.
21. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP and Hung MC. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005; 310(5746):306-310.
22. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011; 19(1):86-100.
23. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-629.
24. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010; 18(2):185-197.
25. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, Noske DP, Tannous BA and Wurdinger T. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 2010; 1(8):710-720.
26. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC and Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 2011; 43(2):285-298.
27. He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, Gill P, Cannon M and Gao SJ. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res. 2012; 72(14):3582-3592.
28. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO and Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012; 56(2):622-631.
29. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE and Chen Y. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013; 144(5):1086-1097 e1089.
30. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011; 20(2):187-199.
31. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, Shinomura Y, Imai K and Toyota M. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res. 2011; 71(17):5646-5658.
32. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Shozu M, Okamoto Y and Seki N. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2011; 2(1-2):29-42.
33. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and Seki N. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012; 106(2):405-413.
34. Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, Jiang C, Dai Y, Guo X and Xiang J. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012; 5:3.
35. Wu CD, Kuo YS, Wu HC and Lin CT. MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci. 2011; 18(1):80.
36. Knowles J, Loizidou M and Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol. 2005; 3(4):309-314.
37. Nelson J, Bagnato A, Battistini B and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003; 3(2):110-116.
38. Grant K, Loizidou M and Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003; 88(2):163-166.
39. Wen YF, Qi B, Liu H, Mo HY, Chen QY, Li J, Huang PY, Ye YF, Zhang Y, Deng MQ, Guo X, Hong MH, Cao KJ and Mai HQ. Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma. Clin Cancer Res. 2011; 17(8):2451-2458.
40. Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY, Deng MQ, Min HQ and Hong MH. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer. 2006; 106(7):1548-1553.
41. Chen Y, Lin MC, Wang H, Chan CY, Jiang L, Ngai SM, Yu J, He ML, Shaw PC, Yew DT, Sung JJ and Kung HF. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics. 2007; 7(17):3097-3104.
42. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007; 46(1):200-208.
43. Tiscornia G, Singer O and Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006; 1(1):241-245.
44. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-408.
45. Wu MH, Huang CY, Lin JA, Wang SW, Peng CY, Cheng HC and Tang CH. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014; 33(13):1725-1735.
46. Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K and Wang P. Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res. 2013; 73(18):5742-5753.
47. Li XP, Li CY, Li X, Ding Y, Chan LL, Yang PH, Li G, Liu X, Lin JS, Wang J, He M, Kung HF, Lin MC and Peng Y. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol Cancer Ther. 2006; 5(5):1290-1298.